drugset / Trial / NCT06969573
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
RandomizedCrossoverTriple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
Timeline
- Start
- 2025-06-05
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil | Other / unclassified | 36 ug | Inhaled |
| Subject | Treprostinil | Other / unclassified | 78 ug | Inhaled |